Review

stat3 sequences (Addgene inc)

Addgene inc is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Addgene inc stat3 sequences
$(A) Immunoblots for pY705 <t>STAT3,</t> pS727 STAT3, and total STAT3 in Trp53/Pten −/− cells that are ispinesib naive and resistant. (B–D) Quantitation of total STAT3/β actin (B), pY705 STAT3/total STAT3 (C), and pS727 STAT3/total STAT3 (D) in ispinesib-naive (blue) and -resistant (red) cells, with three biological replicates of each. Statistical significance assessed with a two-tailed t test. (E and F) Western blot intensity, normalized to β actin, of pY705 STAT3 (E) and pS727 STAT3 (F) in ispinesib-naive (Naive) and -resistant (Res) cells, with the former treated with DMSO vehicle (Veh) and the latter treated with DMSO vehicle (Veh), 500 nM saracatinib (Sara), or 500 nM dasatinib (Dasa). (G) Western blot intensity, normalized to β actin, of total STAT3 in ispinesib-naive (Naive) and -resistant (Res) cells, with the former treated with DMSO vehicle (Veh) and the latter treated with DMSO vehicle (Veh), 500 nM saracatinib (Sara), or 500 nM dasatinib (Dasa). For (E)–(G), please refer to and for the corresponding images of the western blots. Statistical significance determined using a pairwise two-tailed t test. (H–J) Quantitation of pY705 STAT3 (H), pS727 STAT3 (I), and total STAT3 (J), all normalized to β actin for ispinesib-naive cells treated with vehicle (solid blue circles; Naive Veh), ispinesib-resistant cells treated with vehicle (solid red circles; Res Veh), and ispinesib-resistant cells treated with 500 nM erlotinib (open red circles; Res Erlot). Statistical significance was determined by pairwise two-tailed t test. For (H)–(J), please refer to for the corresponding images of the western blots. (K) Dose-response curves for ispinesib-naive (solid blue circles) and -resistant (solid red circles) cells in the absence and presence of 75 nM ispinesib (open red circles) for the STAT3 inhibitor SH5–07. (L and M) Effect of shRNA suppression of STAT3 on ispinesib resistance. Please refer to for the corresponding western blot for STAT3, which shows >90% knockdown with two STAT3-directed shRNAs. Statistical significance determined using a pairwise two-tailed t test. (N) Ispinesib-naive and -resistant cells were treated for 24 h with 1 μM doxorubicin, and cell lysates were probed by western blot for full-length caspase 3 (FL Caspase 3) and cleaved caspase 3 (Cl Caspase 3). (O) Ispinesib-naive and -resistant cells were lysed, and mitochondria (Mito) were separated from the cytoplasm (Cyto) by centrifugation. Western blot shows that ispinesib resistance is associated with a marked increase in mitochondrial STAT3 that is phosphorylated on S727. Loading controls include α tubulin for the cytoplasmic and cytochrome c oxidase ( COX4 ) for the mitochondrial fractions. (P) Ispinesib-naive and -resistant cells were lysed, and nuclei (Nuc) were separated from the cytoplasm (Cyto) by centrifugation. Western blot shows that ispinesib resistance is associated with a marked increase in nuclear STAT3 that is phosphorylated on Y705. Loading controls include a tubulin for the cytoplasmic and histone H3 for the nuclear fractions. (Q) Ispinesib-naive cells were transfected with STAT3 S727A, STAT3 S727D, STAT3-C, or STAT3 S727D + STAT3-C constructs, each fused to the FLAG epitope. After confirmation of expression of the STAT3 mutant , cells were treated with a range of ispinesib concentrations, and cell viability was measured at 72 h. While transfection of either STAT3-S727D or STAT3-C increases the EC 50 of ispinesib by ~20-fold, co-transfection of both of these constructs is required to increase the ispinesib EC 50 to that seen for ispinesib-resistant cells ( ; ).$
Stat3 Sequences, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stat3+expression+construct/pmc10018805-344-0-9?v=Addgene+inc
Average 94 stars, based on 38 article reviews

stat3 sequences - by Bioz Stars, 2026-08

94/100 stars

Images

1) Product Images from "Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma"

Article Title: Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma

Journal: Cell reports

doi: 10.1016/j.celrep.2022.110991

$(A) Immunoblots for pY705 STAT3, pS727 STAT3, and total STAT3 in Trp53/Pten −/− cells that are ispinesib naive and resistant. (B–D) Quantitation of total STAT3/β actin (B), pY705 STAT3/total STAT3 (C), and pS727 STAT3/total STAT3 (D) in ispinesib-naive (blue) and -resistant (red) cells, with three biological replicates of each. Statistical significance assessed with a two-tailed t test. (E and F) Western blot intensity, normalized to β actin, of pY705 STAT3 (E) and pS727 STAT3 (F) in ispinesib-naive (Naive) and -resistant (Res) cells, with the former treated with DMSO vehicle (Veh) and the latter treated with DMSO vehicle (Veh), 500 nM saracatinib (Sara), or 500 nM dasatinib (Dasa). (G) Western blot intensity, normalized to β actin, of total STAT3 in ispinesib-naive (Naive) and -resistant (Res) cells, with the former treated with DMSO vehicle (Veh) and the latter treated with DMSO vehicle (Veh), 500 nM saracatinib (Sara), or 500 nM dasatinib (Dasa). For (E)–(G), please refer to and for the corresponding images of the western blots. Statistical significance determined using a pairwise two-tailed t test. (H–J) Quantitation of pY705 STAT3 (H), pS727 STAT3 (I), and total STAT3 (J), all normalized to β actin for ispinesib-naive cells treated with vehicle (solid blue circles; Naive Veh), ispinesib-resistant cells treated with vehicle (solid red circles; Res Veh), and ispinesib-resistant cells treated with 500 nM erlotinib (open red circles; Res Erlot). Statistical significance was determined by pairwise two-tailed t test. For (H)–(J), please refer to for the corresponding images of the western blots. (K) Dose-response curves for ispinesib-naive (solid blue circles) and -resistant (solid red circles) cells in the absence and presence of 75 nM ispinesib (open red circles) for the STAT3 inhibitor SH5–07. (L and M) Effect of shRNA suppression of STAT3 on ispinesib resistance. Please refer to for the corresponding western blot for STAT3, which shows >90% knockdown with two STAT3-directed shRNAs. Statistical significance determined using a pairwise two-tailed t test. (N) Ispinesib-naive and -resistant cells were treated for 24 h with 1 μM doxorubicin, and cell lysates were probed by western blot for full-length caspase 3 (FL Caspase 3) and cleaved caspase 3 (Cl Caspase 3). (O) Ispinesib-naive and -resistant cells were lysed, and mitochondria (Mito) were separated from the cytoplasm (Cyto) by centrifugation. Western blot shows that ispinesib resistance is associated with a marked increase in mitochondrial STAT3 that is phosphorylated on S727. Loading controls include α tubulin for the cytoplasmic and cytochrome c oxidase ( COX4 ) for the mitochondrial fractions. (P) Ispinesib-naive and -resistant cells were lysed, and nuclei (Nuc) were separated from the cytoplasm (Cyto) by centrifugation. Western blot shows that ispinesib resistance is associated with a marked increase in nuclear STAT3 that is phosphorylated on Y705. Loading controls include a tubulin for the cytoplasmic and histone H3 for the nuclear fractions. (Q) Ispinesib-naive cells were transfected with STAT3 S727A, STAT3 S727D, STAT3-C, or STAT3 S727D + STAT3-C constructs, each fused to the FLAG epitope. After confirmation of expression of the STAT3 mutant , cells were treated with a range of ispinesib concentrations, and cell viability was measured at 72 h. While transfection of either STAT3-S727D or STAT3-C increases the EC 50 of ispinesib by ~20-fold, co-transfection of both of these constructs is required to increase the ispinesib EC 50 to that seen for ispinesib-resistant cells ( ; ).$
Figure Legend Snippet: (A) Immunoblots for pY705 STAT3, pS727 STAT3, and total STAT3 in Trp53/Pten −/− cells that are ispinesib naive and resistant. (B–D) Quantitation of total STAT3/β actin (B), pY705 STAT3/total STAT3 (C), and pS727 STAT3/total STAT3 (D) in ispinesib-naive (blue) and -resistant (red) cells, with three biological replicates of each. Statistical significance assessed with a two-tailed t test. (E and F) Western blot intensity, normalized to β actin, of pY705 STAT3 (E) and pS727 STAT3 (F) in ispinesib-naive (Naive) and -resistant (Res) cells, with the former treated with DMSO vehicle (Veh) and the latter treated with DMSO vehicle (Veh), 500 nM saracatinib (Sara), or 500 nM dasatinib (Dasa). (G) Western blot intensity, normalized to β actin, of total STAT3 in ispinesib-naive (Naive) and -resistant (Res) cells, with the former treated with DMSO vehicle (Veh) and the latter treated with DMSO vehicle (Veh), 500 nM saracatinib (Sara), or 500 nM dasatinib (Dasa). For (E)–(G), please refer to and for the corresponding images of the western blots. Statistical significance determined using a pairwise two-tailed t test. (H–J) Quantitation of pY705 STAT3 (H), pS727 STAT3 (I), and total STAT3 (J), all normalized to β actin for ispinesib-naive cells treated with vehicle (solid blue circles; Naive Veh), ispinesib-resistant cells treated with vehicle (solid red circles; Res Veh), and ispinesib-resistant cells treated with 500 nM erlotinib (open red circles; Res Erlot). Statistical significance was determined by pairwise two-tailed t test. For (H)–(J), please refer to for the corresponding images of the western blots. (K) Dose-response curves for ispinesib-naive (solid blue circles) and -resistant (solid red circles) cells in the absence and presence of 75 nM ispinesib (open red circles) for the STAT3 inhibitor SH5–07. (L and M) Effect of shRNA suppression of STAT3 on ispinesib resistance. Please refer to for the corresponding western blot for STAT3, which shows >90% knockdown with two STAT3-directed shRNAs. Statistical significance determined using a pairwise two-tailed t test. (N) Ispinesib-naive and -resistant cells were treated for 24 h with 1 μM doxorubicin, and cell lysates were probed by western blot for full-length caspase 3 (FL Caspase 3) and cleaved caspase 3 (Cl Caspase 3). (O) Ispinesib-naive and -resistant cells were lysed, and mitochondria (Mito) were separated from the cytoplasm (Cyto) by centrifugation. Western blot shows that ispinesib resistance is associated with a marked increase in mitochondrial STAT3 that is phosphorylated on S727. Loading controls include α tubulin for the cytoplasmic and cytochrome c oxidase ( COX4 ) for the mitochondrial fractions. (P) Ispinesib-naive and -resistant cells were lysed, and nuclei (Nuc) were separated from the cytoplasm (Cyto) by centrifugation. Western blot shows that ispinesib resistance is associated with a marked increase in nuclear STAT3 that is phosphorylated on Y705. Loading controls include a tubulin for the cytoplasmic and histone H3 for the nuclear fractions. (Q) Ispinesib-naive cells were transfected with STAT3 S727A, STAT3 S727D, STAT3-C, or STAT3 S727D + STAT3-C constructs, each fused to the FLAG epitope. After confirmation of expression of the STAT3 mutant , cells were treated with a range of ispinesib concentrations, and cell viability was measured at 72 h. While transfection of either STAT3-S727D or STAT3-C increases the EC 50 of ispinesib by ~20-fold, co-transfection of both of these constructs is required to increase the ispinesib EC 50 to that seen for ispinesib-resistant cells ( ; ).

Techniques Used: Western Blot, Quantitation Assay, Two Tailed Test, shRNA, Knockdown, Centrifugation, Transfection, Construct, FLAG-tag, Expressing, Mutagenesis, Cotransfection

(A) Western blots of two human GBM lines (L1 and 120) show no significant upregulation of Kif15 between ispinesib-naive ( N ) and -resistant ( R ) lines. Significance determined by a two-tailed t test. (B) Expression of EGFR is increased 3- to 4-fold in resistant ( R ) L1 and 120 GBM lines compared with the corresponding drug-naive ( N ) lines. Statistical significance determined using a pairwise two-tailed t test. (C–H) Phosphorylation of STAT3 increases in the human GBM cell lines L1 and 120 with development of ispinesib resistance. (C) Western blot for pY705, pS727, and total STAT3 in ispinesib naive ( N ) and resistant ( R ) GBM L1 and 120 cell lines. (D–H) Quantitation of total STAT3/β actin (D), pY705 STAT3/total STAT3 (E), pS727 STAT3/total STAT3 (F), pY705 STAT3/β actin (G), and pS727 STAT3/β actin (H) in ispinesib-naive ( N ) and -resistant ( R ) L1 and 120 cell lines. Statistical significance was determined by a two-tailed t test. Statistical significance determined using a pairwise two-tailed t test. (I–L) Ispinesib resistance in human L1 and 120 GBM cell lines can be reversed with saracatinib and SH5–07 but not with either erlotinib or dasatinib. (I and J) Dose-response curves for dasatinib (I) and erlotinib (J) show no effect of either drug as a single agent on ispinesib-naive (blue) or -resistant (red) cell lines, the latter in the presence of 50 nM ispinesib. (J and K) By contrast, both saracatinib (K) and SH5–07 (L) are active against ispinesib-resistant L1 and 120 cells in the presence of 50 nM ispinesib (red curves) but not against ispinesib-naive (blue curves) L1 and 120 cells. Relevant EC 50 values are listed in .

Figure Legend Snippet: (A) Western blots of two human GBM lines (L1 and 120) show no significant upregulation of Kif15 between ispinesib-naive ( N ) and -resistant ( R ) lines. Significance determined by a two-tailed t test. (B) Expression of EGFR is increased 3- to 4-fold in resistant ( R ) L1 and 120 GBM lines compared with the corresponding drug-naive ( N ) lines. Statistical significance determined using a pairwise two-tailed t test. (C–H) Phosphorylation of STAT3 increases in the human GBM cell lines L1 and 120 with development of ispinesib resistance. (C) Western blot for pY705, pS727, and total STAT3 in ispinesib naive ( N ) and resistant ( R ) GBM L1 and 120 cell lines. (D–H) Quantitation of total STAT3/β actin (D), pY705 STAT3/total STAT3 (E), pS727 STAT3/total STAT3 (F), pY705 STAT3/β actin (G), and pS727 STAT3/β actin (H) in ispinesib-naive ( N ) and -resistant ( R ) L1 and 120 cell lines. Statistical significance was determined by a two-tailed t test. Statistical significance determined using a pairwise two-tailed t test. (I–L) Ispinesib resistance in human L1 and 120 GBM cell lines can be reversed with saracatinib and SH5–07 but not with either erlotinib or dasatinib. (I and J) Dose-response curves for dasatinib (I) and erlotinib (J) show no effect of either drug as a single agent on ispinesib-naive (blue) or -resistant (red) cell lines, the latter in the presence of 50 nM ispinesib. (J and K) By contrast, both saracatinib (K) and SH5–07 (L) are active against ispinesib-resistant L1 and 120 cells in the presence of 50 nM ispinesib (red curves) but not against ispinesib-naive (blue curves) L1 and 120 cells. Relevant EC 50 values are listed in .

Techniques Used: Western Blot, Two Tailed Test, Expressing, Phospho-proteomics, Quantitation Assay

(A) Uniform manifold approximation and projection (UMAP) of all cells in the dataset, annotated by whether they are part of the naive or resistant populations. (B) Co-expression analysis of EGFR and SRC transcripts on original dataset. Cells were deemed EGFR or SRC positive based on whether they express any transcripts of the respective gene. See for subsample analysis to equalize coverage across conditions before doing co-expression analysis. (C) Cluster-by-cluster gene set enrichment analysis (GSEA) of the Cancer Hallmarks ‘‘IL6_JAK_STAT3_SIGNALING’’ pathway. Each cluster is colored based on its normalized enrichment score (NES) for the pathway. (D) GSEA of same IL-6/JAK/STAT3 pathway comparing all resistant cells with all naive cells. Normalized enrichment score, as well as p value and false discovery rate (FDR) q value, are displayed.

Figure Legend Snippet: (A) Uniform manifold approximation and projection (UMAP) of all cells in the dataset, annotated by whether they are part of the naive or resistant populations. (B) Co-expression analysis of EGFR and SRC transcripts on original dataset. Cells were deemed EGFR or SRC positive based on whether they express any transcripts of the respective gene. See for subsample analysis to equalize coverage across conditions before doing co-expression analysis. (C) Cluster-by-cluster gene set enrichment analysis (GSEA) of the Cancer Hallmarks ‘‘IL6_JAK_STAT3_SIGNALING’’ pathway. Each cluster is colored based on its normalized enrichment score (NES) for the pathway. (D) GSEA of same IL-6/JAK/STAT3 pathway comparing all resistant cells with all naive cells. Normalized enrichment score, as well as p value and false discovery rate (FDR) q value, are displayed.

Techniques Used: Expressing

Figure Legend Snippet: KEY RESOURCES TABLE

Techniques Used: Virus, Plasmid Preparation, Recombinant, Membrane, Protease Inhibitor, Western Blot, Lysis, Transfection, Bicinchoninic Acid Protein Assay, Isolation, Cell Culture, Extraction, Software, Gene Expression, Mass Spectrometry

Image Search Results

A , B Role of ELK1, STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.

Journal: Cell Death & Disease

Article Title: Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer

doi: 10.1038/s41419-025-07481-8

Figure Lengend Snippet: A , B Role of ELK1, STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.

Article Snippet: The GV492 lentiviral expression constructs of human ELK1, ELK3, ELK4, STAT3, SRF, as well as the GV366 (C-terminally HA-tagged) and GV657 (C-terminally Flag-tagged) constructs for transient expression of human STAT3 and SRF were purchased from Shanghai Genechem Co., Ltd.

Techniques: Activity Assay, Expressing, Plasmid Preparation, Quantitative RT-PCR, Western Blot, Luciferase, Binding Assay, Control, Co-Immunoprecipitation Assay, Transfection, Immunoprecipitation, Over Expression, Inhibition

Figure 2. Analysis of STAT3 in HL cell lines. (A) RQ-PCR analysis of STAT3 in eight HL cell lines (left). Western blot analysis of three HL cell lines for STAT3, phospho (P)-STAT3 and alpha-tubulin (TUBA) as control (right). (B) Immuno-cytological microscopy of untreated AM-HLH cells (left) stained for STAT3 (green) and the nucleus (blue). Forced expression of GFP-labeled STAT3 in transfected AM- HLH (right). White arrowheads indicate transfected nuclei demonstrating reduced STAT3 protein in the nucleus as compared to the cytoplasm. The light blue arrowhead indicates a non-transfected cell. (C) Western blot analysis of IL6-treated AM-HLH for STAT3, P-STAT3 and TUBA (left). Immuno- cytological microscopy of IL6-treated AM-HLH cells stained for STAT3 (green) and the nucleus (blue) (middle). RQ-PCR analysis of HLX in IL6-treated AM-HLH after 4 h (right). (D) Immuno-cytological microscopy of control and TSA-treated L-540 cells stained for STAT3 (green) and the nucleus (blue). (E) RQ-PCR analysis of HLX in L-540 (left) AM-HLH (right) treated with TSA. Statistical signiﬁcance was assessed by t-test and derived p-values indicated by asterisks (** p < 0.01, *** p < 0.001, n.s., not signiﬁcant).

Journal: Biomedicines

Article Title: Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.

doi: 10.3390/biomedicines10071608

Figure Lengend Snippet: Figure 2. Analysis of STAT3 in HL cell lines. (A) RQ-PCR analysis of STAT3 in eight HL cell lines (left). Western blot analysis of three HL cell lines for STAT3, phospho (P)-STAT3 and alpha-tubulin (TUBA) as control (right). (B) Immuno-cytological microscopy of untreated AM-HLH cells (left) stained for STAT3 (green) and the nucleus (blue). Forced expression of GFP-labeled STAT3 in transfected AM- HLH (right). White arrowheads indicate transfected nuclei demonstrating reduced STAT3 protein in the nucleus as compared to the cytoplasm. The light blue arrowhead indicates a non-transfected cell. (C) Western blot analysis of IL6-treated AM-HLH for STAT3, P-STAT3 and TUBA (left). Immuno- cytological microscopy of IL6-treated AM-HLH cells stained for STAT3 (green) and the nucleus (blue) (middle). RQ-PCR analysis of HLX in IL6-treated AM-HLH after 4 h (right). (D) Immuno-cytological microscopy of control and TSA-treated L-540 cells stained for STAT3 (green) and the nucleus (blue). (E) RQ-PCR analysis of HLX in L-540 (left) AM-HLH (right) treated with TSA. Statistical signiﬁcance was assessed by t-test and derived p-values indicated by asterisks (** p < 0.01, *** p < 0.001, n.s., not signiﬁcant).

Article Snippet: A green fluorescence protein (GFP)-labeled STAT3 expression construct was cloned into vector pCMV6-XL4 and obtained from Origene (Wiesbaden, Germany).

Techniques: Western Blot, Control, Microscopy, Staining, Expressing, Labeling, Transfection, Derivative Assay

Figure 4. Knockdown and stimulation studies in AM-HLH and L-540. (A) SiRNA-mediated knock- down of IRF4 in AM-HLH resulted in elevated expression of STAT3 as analyzed by RQ-PCR (left). The

Journal: Biomedicines

Article Title: Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.

doi: 10.3390/biomedicines10071608

Figure Lengend Snippet: Figure 4. Knockdown and stimulation studies in AM-HLH and L-540. (A) SiRNA-mediated knock- down of IRF4 in AM-HLH resulted in elevated expression of STAT3 as analyzed by RQ-PCR (left). The

Article Snippet: A green fluorescence protein (GFP)-labeled STAT3 expression construct was cloned into vector pCMV6-XL4 and obtained from Origene (Wiesbaden, Germany).

Techniques: Knockdown, Expressing

Figure 6. Summary of the results from this study showing a gene regulatory network around STAT3. Genomic ampliﬁcations targeting particular genes are highlighted by a red background. Elevated genes are indicated in red, low level expressed genes in green while medium level expressed genes are shown in black. Functional consequences including immune escape, EBV activity, proliferation and survival are highlighted by a blue background. Bold lines indicate relationships demonstrated in this study while slight lines refer to published data.

Journal: Biomedicines

Article Title: Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.

doi: 10.3390/biomedicines10071608

Figure Lengend Snippet: Figure 6. Summary of the results from this study showing a gene regulatory network around STAT3. Genomic ampliﬁcations targeting particular genes are highlighted by a red background. Elevated genes are indicated in red, low level expressed genes in green while medium level expressed genes are shown in black. Functional consequences including immune escape, EBV activity, proliferation and survival are highlighted by a blue background. Bold lines indicate relationships demonstrated in this study while slight lines refer to published data.

Article Snippet: A green fluorescence protein (GFP)-labeled STAT3 expression construct was cloned into vector pCMV6-XL4 and obtained from Origene (Wiesbaden, Germany).

Techniques: Functional Assay, Activity Assay

Shikonin inhibited STAT3 signaling pathway in melanoma cells. (A) Cells were treated with indicated concentration of shikonin for 24 h, expression levels of STAT3 and p-STAT3 were determined by the Western blot analysis (upper), and relative expression levels were analyzed by Image J software (bottom). (B) Cells were treated with 2 μM shikonin for 24 h, and then incubated with DSS. Changes in STAT3 dimerization were evaluated by immunoblotting. The arrows indicated the dimer (D) and the monomer (M) STAT3. The representative results (upper) and the relative expression levels of dimer STAT3 (bottom) were shown. (C, D) Cells were treated with indicated concentration of shikonin for 24 h, and then the intracellular distribution of STAT3 was analyzed by immunofluorescence assay (C) and immunoblotting (D) . Relative expression levels of cytosolic and nuclear STAT3 were also shown (bottom). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01.

Journal: Frontiers in Pharmacology

Article Title: Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

doi: 10.3389/fphar.2020.00748

Figure Lengend Snippet: Shikonin inhibited STAT3 signaling pathway in melanoma cells. (A) Cells were treated with indicated concentration of shikonin for 24 h, expression levels of STAT3 and p-STAT3 were determined by the Western blot analysis (upper), and relative expression levels were analyzed by Image J software (bottom). (B) Cells were treated with 2 μM shikonin for 24 h, and then incubated with DSS. Changes in STAT3 dimerization were evaluated by immunoblotting. The arrows indicated the dimer (D) and the monomer (M) STAT3. The representative results (upper) and the relative expression levels of dimer STAT3 (bottom) were shown. (C, D) Cells were treated with indicated concentration of shikonin for 24 h, and then the intracellular distribution of STAT3 was analyzed by immunofluorescence assay (C) and immunoblotting (D) . Relative expression levels of cytosolic and nuclear STAT3 were also shown (bottom). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01.

Article Snippet: Constitutively active STAT3 expression construct STAT3-C Flag pRc/CMV was obtained from Addgene (USA).

Techniques: Concentration Assay, Expressing, Western Blot, Software, Incubation, Immunofluorescence

Shikonin down-regulated protein levels and inhibited enzymatic activities of STAT3-targeted molecules in melanoma cells. A375 and A2058 cells were treated with indicated concentrations of shikonin for 24 h, and then total cell lysates were collected, expression levels of (A) Mcl-1, Bcl-2, (B) MMP-2, (D) Twist, Vimentin, and N-cadherin were evaluated by Western blot analysis (left) and relative expression levels were analyzed by Image J software (right). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01. (C) The enzymatic activities of MMP-2 and MMP-9 were determined by gelatinase zymography.

Journal: Frontiers in Pharmacology

Article Title: Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

doi: 10.3389/fphar.2020.00748

Figure Lengend Snippet: Shikonin down-regulated protein levels and inhibited enzymatic activities of STAT3-targeted molecules in melanoma cells. A375 and A2058 cells were treated with indicated concentrations of shikonin for 24 h, and then total cell lysates were collected, expression levels of (A) Mcl-1, Bcl-2, (B) MMP-2, (D) Twist, Vimentin, and N-cadherin were evaluated by Western blot analysis (left) and relative expression levels were analyzed by Image J software (right). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01. (C) The enzymatic activities of MMP-2 and MMP-9 were determined by gelatinase zymography.

Article Snippet: Constitutively active STAT3 expression construct STAT3-C Flag pRc/CMV was obtained from Addgene (USA).

Techniques: Expressing, Western Blot, Software, Zymography

Overexpression of STAT3 in human melanoma A375 cells reduced shikonin-mediated cell growth, migration, and invasion inhibition. A375 cells were transiently transfected with an empty vector or a STAT3C-expressing construct for 24 h, and then (A) the expression level of STAT3 in A375-STAT3C cells and A375-EV cells were examined by immunoblotting. (B–D) A375-EV or A375-STAT3C cells were incubated with shikonin for 48 h or 24 h, and then (B) cell proliferation, (C) cell migratory, and (D) cell invasive abilities were measured. Representative photographs of migrated cells (left) and quantification of these cells (right) were shown. Data were mean ± SD from three independent experiments, ## P < 0.01, * P < 0.05, and ** P < 0.01.

Journal: Frontiers in Pharmacology

Article Title: Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

doi: 10.3389/fphar.2020.00748

Figure Lengend Snippet: Overexpression of STAT3 in human melanoma A375 cells reduced shikonin-mediated cell growth, migration, and invasion inhibition. A375 cells were transiently transfected with an empty vector or a STAT3C-expressing construct for 24 h, and then (A) the expression level of STAT3 in A375-STAT3C cells and A375-EV cells were examined by immunoblotting. (B–D) A375-EV or A375-STAT3C cells were incubated with shikonin for 48 h or 24 h, and then (B) cell proliferation, (C) cell migratory, and (D) cell invasive abilities were measured. Representative photographs of migrated cells (left) and quantification of these cells (right) were shown. Data were mean ± SD from three independent experiments, ## P < 0.01, * P < 0.05, and ** P < 0.01.

Article Snippet: Constitutively active STAT3 expression construct STAT3-C Flag pRc/CMV was obtained from Addgene (USA).

Techniques: Over Expression, Migration, Inhibition, Transfection, Plasmid Preparation, Expressing, Construct, Western Blot, Incubation

Review

Structured Review

Images

1) Product Images from "Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma"

Similar Products

Image Search Results